(MedPage Today) — Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 receptor agonist, an open…
Source link : https://www.medpagetoday.com/endocrinology/diabetes/114983
Author :
Publish date : 2025-04-04 21:35:00
Copyright for syndicated content belongs to the linked Source.
